373 related articles for article (PubMed ID: 30463937)
1. An investigational RNAi therapeutic targeting Factor XII (ALN-F12) for the treatment of hereditary angioedema.
Liu J; Qin J; Borodovsky A; Racie T; Castoreno A; Schlegel M; Maier MA; Zimmerman T; Fitzgerald K; Butler J; Akinc A
RNA; 2019 Feb; 25(2):255-263. PubMed ID: 30463937
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of liver-derived factor XII by GalNAc-siRNA ALN-F12 prevents thrombosis in mice without impacting hemostatic function.
Liu J; Cooley BC; Akinc A; Butler J; Borodovsky A
Thromb Res; 2020 Dec; 196():200-205. PubMed ID: 32896690
[TBL] [Abstract][Full Text] [Related]
3. Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations.
de Maat S; Björkqvist J; Suffritti C; Wiesenekker CP; Nagtegaal W; Koekman A; van Dooremalen S; Pasterkamp G; de Groot PG; Cicardi M; Renné T; Maas C
J Allergy Clin Immunol; 2016 Nov; 138(5):1414-1423.e9. PubMed ID: 27130860
[TBL] [Abstract][Full Text] [Related]
4. A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain.
Ivanov I; Matafonov A; Sun MF; Mohammed BM; Cheng Q; Dickeson SK; Kundu S; Verhamme IM; Gruber A; McCrae K; Gailani D
Blood; 2019 Mar; 133(10):1152-1163. PubMed ID: 30591525
[TBL] [Abstract][Full Text] [Related]
5. Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment.
Zeerleder S; Levi M
Ann Med; 2016; 48(4):256-67. PubMed ID: 27018196
[TBL] [Abstract][Full Text] [Related]
6. Hereditary angioedema with normal C1-INH with versus without specific F12 gene mutations.
Bork K; Wulff K; Witzke G; Hardt J
Allergy; 2015 Aug; 70(8):1004-12. PubMed ID: 25952149
[TBL] [Abstract][Full Text] [Related]
7. Biochemistry, molecular genetics, and clinical aspects of hereditary angioedema with and without C1 inhibitor deficiency.
Miyata T; Horiuchi T
Allergol Int; 2023 Jul; 72(3):375-384. PubMed ID: 37169642
[TBL] [Abstract][Full Text] [Related]
8. Current update on cellular and molecular mechanisms of hereditary angioedema.
Walford HH; Zuraw BL
Ann Allergy Asthma Immunol; 2014 May; 112(5):413-8. PubMed ID: 24484972
[TBL] [Abstract][Full Text] [Related]
9. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway.
Kaplan AP; Joseph K
Adv Immunol; 2014; 121():41-89. PubMed ID: 24388213
[TBL] [Abstract][Full Text] [Related]
10. Impaired control of the contact system in hereditary angioedema with normal C1-inhibitor.
Bova M; Suffritti C; Bafunno V; Loffredo S; Cordisco G; Del Giacco S; De Pasquale TMA; Firinu D; Margaglione M; Montinaro V; Petraroli A; Radice A; Brussino L; Zanichelli A; Zoli A; Cicardi M
Allergy; 2020 Jun; 75(6):1394-1403. PubMed ID: 31860755
[TBL] [Abstract][Full Text] [Related]
11. Characterization of patients with angioedema without wheals: the importance of F12 gene screening.
Firinu D; Bafunno V; Vecchione G; Barca MP; Manconi PE; Santacroce R; Margaglione M; Del Giacco SR
Clin Immunol; 2015 Apr; 157(2):239-48. PubMed ID: 25744496
[TBL] [Abstract][Full Text] [Related]
12. Hereditary Angioedema with Normal C1 Inhibitor and F12 Mutations in 42 Brazilian Families.
Veronez CL; Moreno AS; Constantino-Silva RN; Maia LSM; Ferriani MPL; Castro FFM; Valle SR; Nakamura VK; Cagini N; Gonçalves RF; Mansour E; Serpa FS; Coelho Dias GA; Piccirillo MA; Toledo E; de Souza Bernardes M; Cichon S; Stieber C; Arruda LK; Pesquero JB; Grumach AS
J Allergy Clin Immunol Pract; 2018; 6(4):1209-1216.e8. PubMed ID: 29128335
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of vascular permeability by antisense-mediated inhibition of plasma kallikrein and coagulation factor 12.
Bhattacharjee G; Revenko AS; Crosby JR; May C; Gao D; Zhao C; Monia BP; MacLeod AR
Nucleic Acid Ther; 2013 Jun; 23(3):175-87. PubMed ID: 23582057
[TBL] [Abstract][Full Text] [Related]
14. Analysis of cold activation of the contact system in hereditary angioedema with normal C1 inhibitor.
Larrauri B; Hester CG; Jiang H; Miletic VD; Malbran A; Bork K; Kaplan A; Frank M
Mol Immunol; 2021 Aug; 136():150-160. PubMed ID: 34153620
[TBL] [Abstract][Full Text] [Related]
15. Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III.
Björkqvist J; de Maat S; Lewandrowski U; Di Gennaro A; Oschatz C; Schönig K; Nöthen MM; Drouet C; Braley H; Nolte MW; Sickmann A; Panousis C; Maas C; Renné T
J Clin Invest; 2015 Aug; 125(8):3132-46. PubMed ID: 26193639
[TBL] [Abstract][Full Text] [Related]
16. Factor XII-independent activation of the bradykinin-forming cascade: Implications for the pathogenesis of hereditary angioedema types I and II.
Joseph K; Tholanikunnel BG; Bygum A; Ghebrehiwet B; Kaplan AP
J Allergy Clin Immunol; 2013 Aug; 132(2):470-5. PubMed ID: 23672780
[TBL] [Abstract][Full Text] [Related]
17. Treatment for hereditary angioedema with normal C1-INH and specific mutations in the F12 gene (HAE-FXII).
Bork K; Wulff K; Witzke G; Hardt J
Allergy; 2017 Feb; 72(2):320-324. PubMed ID: 27905115
[TBL] [Abstract][Full Text] [Related]
18. Hereditary angioedema: Pathophysiology (HAE type I, HAE type II, and HAE nC1-INH).
Wedner HJ
Allergy Asthma Proc; 2020 Nov; 41(Suppl 1):S14-S17. PubMed ID: 33109319
[TBL] [Abstract][Full Text] [Related]
19. Pathophysiology of hereditary angioedema.
Zuraw BL; Christiansen SC
Am J Rhinol Allergy; 2011; 25(6):373-8. PubMed ID: 22185738
[TBL] [Abstract][Full Text] [Related]
20. Hereditary angioedema with normal C1 inhibitor: clinical characteristics and treatment response with plasma-derived human C1 inhibitor concentrate (Berinert
Bouillet L; Boccon-Gibod I; Gompel A; Floccard B; Martin L; Blanchard-Delaunay C; Launay D; Fain O
Eur J Dermatol; 2017 Apr; 27(2):155-159. PubMed ID: 28251901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
